A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus

Exclusion Criteria

• •Subjects with Type 1 diabetes mellitus or secondary diabetes mellitus (i.e. any type other than T2DM)
• •Female subject is pregnant (confirmed by laboratory testing), planning a pregnancy or lactating.
• •History of cancer that has not been in full remission for at least 3 years before screening.
• •History of thyroid cancer.
• •Personal history or family history of thyroid medullary carcinoma or multiple endocrine neoplasia type 2 (MEN2).
• •History of pancreatitis or considered clinically at significant risk of developing pancreatitis during the course of the study (e.g. due to symptomatic gallstones).
• •Severe gastroparesis within 6 months prior to screening.
• •History of significant gastrointestinal (GI) surgery that in the opinion of the investigator is likely to significantly affect upper GI or pancreatic function.
• •Have a history of at least one episode of diabetic ketoacidosis (DKA) after receiving anti-diabetic medication.
• •Fasting triglyceride level more than 750 mg/dL at screening.
• •Serum calcitonin more than 50 picogram (pg/mL) at screening.
• •Hemoglobinopathy that may affect determination of HbA1c.
• •Uncontrolled hypertension at screening.
• •Estimated Glomerular Filtration Rate (eGFR) less than 90 mL/minute/1.73 meter\^2 (calculated using the Schwartz equation) at screening.
• •ALT more than 2.5x upper limit of normal (ULN) or Bilirubin more than 1.5xULN (isolated bilirubin more than 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin more than 35%) at screening.
• •Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment).
• •Current or previous insulin therapy used for more than 4 weeks (continuously) in the 3 months prior to screening.
• •Use of a GLP-1receptor agonist at study entry and during the study.
• •Any oral diabetic medications, except metformin, at study entry and during the study.
• •Use of oral or systemically injected glucocorticoids is generally not allowed within the 3 months before randomization; however, short courses of oral steroids (single dose or multiple doses for up to 7 days) may be permitted provided these cases are discussed with the medical monitor.
• •Weight loss medications.
• •Antiretroviral drugs.
• •Known allergy or serious hypersensitivity reaction to albiglutide or any product components (including yeast and human albumin), any other GLP 1 analogue, insulin, or other study medication's excipients or other contraindications.
• •Any other reason the investigator deems the subject to be unsuitable for the study or may interfere with trial compliance (e.g. significant medical or psychiatric history).
• •The subject has participated in a clinical trial and has received an investigational product or device within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).